All Hot News Popular Media
«Merck» All Releases

Mon, 02 Jul 2018 10:45:00 +0000
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
Dateline City:
KENILWORTH, N.J.

Application Based on Monotherapy Data from Phase 2 KEYNOTE-224 Trial

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC).

Language:
English
Contact:

Merck
Media
Pamela Eisele, 267-305-3558
or
Ann Bush, 908-740-6677
or
Investors
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more


Mon, 02 Jul 2018 10:30:00 +0000
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-Small Cell Lung Cancer
Dateline City:
KENILWORTH, N.J.

Application Based on Data from Pivotal Phase 3 KEYNOTE-407 Trial

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, (267) 305-3558
or
Kristen Drake, (908) 334-4688
or
Investor:
Teri Loxam, (908) 740-1986
or
Michael DeCarbo, (908) 740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 02 Jul 2018 06:00:00 +0000
Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from the company are scheduled to be presented at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27 in Amsterdam. Presentations include Week 96 data from the Phase 3 DRIVE-FORWARD clinical trial for doravirine (DOR) and additional analyses for DOR and investigational therapy MK-8591.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Carmen de Gourville, 267-305-4195
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Wed, 27 Jun 2018 21:00:00 +0000
LYNPARZA® (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer
Dateline City:
KENILWORTH, N.J.

LYNPARZA is the First and Only PARP Inhibitor Approved for Use Beyond Ovarian Cancer

Second Approval in Japan for AstraZeneca and Merck’s LYNPARZA

KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA® (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated (BRCAm), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Michael Close, 267-305-1211
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Wed, 27 Jun 2018 10:45:00 +0000
Merck Announces Findings from WHO-led Study of Investigational Heat-Stable Carbetocin for Preventing Excessive Bleeding After Childbirth
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, through its Merck for Mothers initiative announced study results on an investigational heat-stable formulation of carbetocin for the prevention of excessive bleeding after childbirth, also known as postpartum haemorrhage (PPH).

Language:
English
Contact:

For Merck & Co., Inc.
Media:
Doris Li, 908-246-5701
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Wed, 27 Jun 2018 06:00:00 +0000
Merck to Hold Second-Quarter 2018 Sales and Earnings Conference Call on July 27
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 27. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 25 Jun 2018 10:30:00 +0000
LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Dateline City:
KENILWORTH, N.J.

LYNPARZA Met Primary Endpoint of Progression-Free Survival in Women with BRCA-Mutated Advanced Ovarian Cancer and Showed a Safety Profile Consistent with Previous Trials

AstraZeneca and Merck's LYNPARZA is the Only PARP Inhibitor to Demonstrate Significant Activity in the First-Line Maintenance Setting

KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the randomized, double-blinded, placebo-controlled, Phase 3 SOLO-1 trial of LYNPARZA® (olaparib) tablets.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, (267) 305-3558
Michael Close, (267) 305-1211
or
Investor:
Teri Loxam, (908) 740-1986
Michael DeCarbo, (908) 740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Sat, 23 Jun 2018 14:00:00 +0000
FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma
Dateline City:
KENILWORTH, N.J.

Application Based on Recurrence-Free Survival Data from Pivotal Phase 3 EORTC1325/KEYNOTE-054 Trial

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act (PDUFA), or target action, date of February 16, 2019.

Language:
English
Contact:

Merck
Media
Pamela Eisele, 267-305-3558
or
Elizabeth Sell, 267-305-3877
or
Investors
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 18 Jun 2018 14:42:45 +0000
Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA® (sitagliptin). In the CompoSIT-I study, initiation of insulin therapy while continuing treatment with JANUVIA resulted in greater blood glucose reductions and more patients reaching A1C goal compared to those who discontinued JANUVIA.

Language:
English
Contact:

Merck
Media:
Pam Eisele, 267-305-3558
or
Megan Wilkinson, 267-305-6463
or
Investors:
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Wed, 13 Jun 2018 20:06:00 +0000
Late-Breaking Data to be Presented from the Comparative Trials with Sitagliptin (CompoSIT) Program on the Continuation of JANUVIA® (sitagliptin) Treatment Among Patients Initiating Insulin Therapy
Dateline City:
KENILWORTH, N.J.

Merck to present new Phase 3 data on JANUVIA, STEGLATRO™ (ertugliflozin), and real-world evidence research at the 78th Scientific Sessions of the American Diabetes Association

KENILWORTH, N.J., June 18, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that 31 studies from Merck’s diabetes portfolio – including new data for JANUVIA® (sitagliptin), STEGLATRO™ (ertugliflozin) and real-world research – will be presented at the 78th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, June 22 - 26, 2018. Presentations include efficacy and safety data for JANUVIA in various settings across the treatment paradigm.

Language:
English

read more


Wed, 13 Jun 2018 10:45:00 +0000
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Dateline City:
KENILWORTH, N.J.

KEYTRUDA is the First Anti-PD-1 Therapy Approved for Adult and Pediatric Patients with Refractory PMBCL or Who Have Relapsed After Two or More Prior Lines of Therapy

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. This indication is approved under the FDA’s accelerated approval regulations based on tumor response rate and durability of response.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Elizabeth Sell, 267-305-3877
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Tue, 12 Jun 2018 20:06:00 +0000
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company’s 9-valent HPV vaccine.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Deb Wambold, 267-305-0642
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 04 Jun 2018 21:00:00 +0000
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)
Dateline City:
KENILWORTH, N.J.

KEYTRUDA Now First Anti-PD-1 Therapy Approved for Patients with Advanced Cervical Cancer and Disease Progression on or After Chemotherapy

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Michael Close, 267-305-1211
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 04 Jun 2018 11:45:00 +0000
LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer
Dateline City:
KENILWORTH, N.J.

LYNPARZA is the First and Only PARP Inhibitor to Demonstrate Activity in Combination with Standard-of-Care Treatment in Prostate Cancer

AstraZeneca and Merck Presented Results of Study 08 at 2018 ASCO Annual Meeting with Simultaneous Publication in The Lancet Oncology

KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data which showed clinical improvement in median radiologic progression-free survival (rPFS) with LYNPARZA® (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a current standard of care, in metastatic castration-resistant prostate cancer (mCRPC). LYNPARZA is being jointly developed and commercialized by AstraZeneca and Merck.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Michael Close, 267-305-1211
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 04 Jun 2018 11:30:00 +0000
Merck’s KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study
Dateline City:
KENILWORTH, N.J.

First-Time KEYTRUDA Monotherapy Phase 2 Data in Advanced SCLC to be Presented Today at 2018 ASCO Annual Meeting

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced interim data from a cohort of the Phase 2 KEYNOTE-158 study evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in patients with previously treated advanced small cell lung cancer (SCLC). Findings showed an overall response rate (ORR) of 18.7 percent in patients in the SCLC cohort (95% CI, 11.8–27.4), the primary endpoint of the study.

Language:
English
Contact:

For Merck & Co., Inc.
Media:
Pamela Eisele, 267-305-3558
or
Kristen Drake, 908-334-4688
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Sun, 03 Jun 2018 22:00:16 +0000
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma
Dateline City:
KENILWORTH, N.J.

New Analysis of Four-Year Data for KEYTRUDA from Phase 3 KEYNOTE-006 Study Showed 86 Percent of Patients Were Progression-Free 20 Months After Completing Two Years of KEYTRUDA

Five-Year Data for KEYTRUDA from Phase 1b KEYNOTE-001 Study Showed Overall Survival Greater Than 40 Percent in Treatment-Na


Sun, 03 Jun 2018 13:00:00 +0000
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types
Dateline City:
Woodcliff Lake, N.J. & Kenilworth, N.J.

First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the head and neck (SCCHN)

Updated results show antitumor activity with a consistent safety profile in advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma (EC)

The LENVIMA/KEYTRUDA combination was recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for advanced RCC

Phase 3 trials underway in advanced RCC (NCT02811861) and advanced EC (NCT03517449)

Woodcliff Lake, N.J. & Kenilworth, N.J., June 3, 2018 – Eisai Inc.

Language:
English

read more


Sun, 03 Jun 2018 11:30:00 +0000
Merck’s KEYTRUDA® (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study
Dateline City:
KENILWORTH, N.J.

First-Time KEYTRUDA Monotherapy Data in Clear Cell RCC to be Presented at 2018 ASCO Annual Meeting

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell carcinoma (RCC). Interim data showed an overall response rate (ORR) of 38.2 percent (95% CI, 29.1-47.9) in patients who received KEYTRUDA monotherapy as first-line therapy, the primary endpoint of the study.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Ann Bush, 908-740-6677
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Sun, 03 Jun 2018 11:30:00 +0000
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study
Dateline City:
KENILWORTH, N.J.

KEYTRUDA Combination Demonstrated Improved Overall Survival Regardless of PD-L1 Expression in Squamous NSCLC

Results to be Presented Today at 2018 ASCO Annual Meeting Also Showed Significant Improvement in Progression-Free Survival for KEYTRUDA Combination

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-407, a pivotal, Phase 3 study evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC).

Language:
English
Contact:

Media:
Pamela Eisele, 267-305-3558
Kristen Drake, 908-334-4688
or
Investors:
Teri Loxam, 908-740-1986
Peter Dannenbaum, 908-740-1037

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Thu, 31 May 2018 12:52:07 +0000
KEYTRUDA® (pembrolizumab) Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 (TPS

Thu, 24 May 2018 23:30:19 +0000
Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection
Dateline City:
KENILWORTH, N.J. & CHARLOTTE, N.C.

Companies working together to address serious public health concerns for at-risk patients

KENILWORTH, N.J. & CHARLOTTE, N.C. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have expanded their preventative and chronic disease care collaboration to include a new effort designed to help reduce the recurrence of Clostridium difficile infection (C. diff).

Language:
English

read more


Wed, 23 May 2018 10:45:00 +0000
Eisai and Merck Provide Update on Supplemental New Drug Application (Snda) for Lenvatinib in First-line Unresectable Hepatocellular Carcinoma
Dateline City:
Woodcliff Lake, NJ and Kenilworth, NJ

Woodcliff Lake, NJ and Kenilworth, NJ, MAY 24, 2018 – Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental New Drug Application (sNDA) for lenvatinib for the potential first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Language:
English

read more


Tue, 22 May 2018 18:21:00 +0000
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial
Dateline City:
KENILWORTH, N.J.

KEYTRUDA Has Now Demonstrated an Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC), met the dual primary endpoints of overall survival (OS) and progression-free survival (PFS).

Language:
English
Contact:

For Merck & Co., Inc.
Media:
Pamela Eisele, 267-305-3558
or
Kristen Drake, 908-334-4688
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Wed, 16 May 2018 21:05:00 +0000
Merck Announces Third-Quarter 2018 Dividend
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.48 per share of the company’s common stock for the third quarter of 2018. Payment will be made on July 9, 2018 to shareholders of record at the close of business on June 15, 2018.

About Merck

Language:
English
Contact:

Merck
Media:
Tracy Ogden, 908-740-1747
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more



New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J.

New and Long-term Overall Survival Data for KEYTRUDA ® (pembrolizumab) in Lung Cancer and Melanoma, Plus New Data in Renal Cell, Cervical, Merkel Cell, and Other Cancers

First-Time Lynparza ® (olaparib) Data in Combination with Abiraterone in Metastatic Prostate Cancer Under Merck and AstraZeneca Strategic Collaboration

New Data in Four Tumor Types Evaluating LENVIMA ® (lenvatinib) in Combination with KEYTRUDA Under Merck and Eisai Strategic Collaboration

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from Merck’s oncology portfolio, anchored by anti-PD-1 therapy KEYTRUDA, will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. More than 140 abstracts in over 25 tumor types have been accepted, including new and long-term data for KEYTRUDA across multiple types of cancer.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Claire Mulhearn, 908-740-6664
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


view page: 25

Nordics offer: Up to 15% off hotels in Sweden, Norway and Finland

Start: 17 Aug 2017 | End: 24 Mar 2018

Decor Under $100

Start: 20 Oct 2017 | End: 01 Feb 2018

Get $20 off when you sign up for the newsletter at Frame Boutique! (New customers only)

Start: 02 Oct 2017 | End: 01 May 2018

Search All Amazon* UK* DE* FR* JP* CA* CN* IT* ES* IN* BR* MX
Booking.com B.V. is based in Amsterdam in the Netherlands. Ready for some statistics? Our 1,534,024 properties, including 860,482 holiday rentals, are located in 123,105 destinations in 229 countries and territories, and are supported internationally by 198 offices in 70 countries.
2013 Copyright © Techhap.com Mobile version 2015 | PeterLife & company
Skimlinks helps publishers monetize editorial content through automated affiliate links for products.
Terms of use Link at is mandatory if site materials are using fully or particulary.
Were treated to the site administrator, a cup of coffee *https://paypal.me/peterlife
Yandex.ru